Lactic acidosis following antiretroviral therapy;Acidosis láctica secundaria a tratamiento antirretroviral: ¿Se puede hacer algo más?

Medicina Clinica

Volumn 125, Issue 6, 2005, Pages 213-214

  Moreno Cuerda, Victor J ^a   Rubio Garcia, Rafael ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ACETYL COENZYME A; DIDANOSINE; GLUCOSE; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZALCITABINE;

CITRIC ACID CYCLE; CLINICAL FEATURE; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; MITOCHONDRIAL TOXICITY;

EID: 23844466209     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13077381     Document Type: Editorial

References (19)

1. Palella F, Delaney K, Moorman A, Loveness MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med. 1998;338:853-60.
2. Mendoza C, Blanco F, Soriano V. Toxicidad mitocondrial de los antirretrovirales: diagnóstico y monitorización. Med Clin (Barc). 2003;121:310-5.
3. Guidelines for the use of antirretroviral agents in HIV-infected adults and adolescents. October 29, 2004. Disponible en: http://www.hivats.org
4. Lewis W, Dalakas M. Mitochondrial toxicity of antiviral drugs. Nature Medicine. 1995;1:417-22.
5. Calza L, Manfredi R, Chiodo F. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antirretroviral therapy. Clin Nutr. 2005;25:5-15.
6. Brinkman K. Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis. 2000;31:167-9.
7. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhovwn B, Ting L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV infected patients. N Engl J Med. 2002;346:811-20.
8. Falcó V, Rodríguez D, Ribera E, Martínez E, Miró JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review. Clin Infect Dis. 2002;34:838-46.
9. Marceau G, Sapin V, Jacomet C, Ughetto S, Cormerais L, Regagnon C. Frequency, risk factors, and outcome of hyperlactatemia in HIV-positive persons: implications for the management of treated patients. Clin Chem. 2003;49:1154-62.
10. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 2002;16:1341-9.
11. Datta D, Moyle G, Mandalia S, Gazzard B. Matched case-control study to evaluate risk factors for hyperlactatemia in HIV patients on antiretroviral therapy. HIV Med. 2003;4:311-4.
12. Polo R, Martínez S, Madrigal P, González-Muñoz M. Factors associated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. J Acquir Immune Defic Syndr. 2003;1:32-6.
13. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;357:280-1.
14. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS. 2001;15:795-7.
15. Claessens YE, Cariou A, Chiche JD, Dauriat G, Dhainaut JF. L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS. 2000;14:472-3.
16. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue induced lactic acidosis. Lancet. 1998;352:291-2.
17. Luzzati R, Del Brove P, Di Perri G, Luzzani A, Concia E. Riboflavin and severe lactic acidosis. Lancet. 1999;353:901-2.
18. Schramm C, Wanitschke R, Galle PR. Thiamine for the treatment for the nucleoside analogue-induced severe lactic acidosis. Eur J Anaesthesiol. 1999;16:733-5.
19. Pedrol E, Ribell M, Deig E, Villà MC, Miró O, Garrabou G, et al. Tratamiento de la hiperlactatemia sintomática y de la acidosis láctica en pacientes con infección por el virus de la inmunodeficiencia humana en tratamiento con inhibidores de la transcriptasa inversa análogos de los nucleòsidos. Med Clin (Barc). 2005;125:201-4.